Brief: Blueprint Medicines Q4 Net Income USD -49.956 Million Vs. IBES Estimate USD -44.7 Million
13/02/2025 12:00
Feb 13 (Reuters) - Blueprint Medicines Q4 product revenue USD 144.125 million. * Q4 EPS USD -0.79 vs. IBES estimate USD -0.7 * Q4 pretax profit USD -49.284 million vs. IBES estimate USD -44.5 million * Q4 operating expenses USD 187.569 million
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G